1
Immune medicine is becoming programmable, but delivery is the bottleneck
Genome editors, vaccines and cell therapies are being pulled into the same clinical conversation, where control of delivery becomes decisive.
Immunology and Immunology and Biotherapies bring the mechanism side of this shift. Recent selections place immunopharmacology beside systems vaccinology, treating immune response not as a single pathway but as a network that can be measured, modulated and designed around.
Genetic Engineering Publications adds the engineering layer. A Nature guide to newer genome editors, a mouse study using in vivo base editing for a progeria model, and a phase 1 report on in vivo generation of CAR T cells show the same problem from different angles: the edit matters, but delivery to the right cells matters just as much.
Virology News widens the clinical horizon. A post on Moderna’s cancer vaccine is framed alongside vaccine and immune-response coverage, suggesting that vaccine design, cell therapy and genome editing are now discussed as parts of one therapeutic toolkit.
The tension is practical. The topic stream is less about a single breakthrough than about whether biology can be programmed safely inside living systems, with enough control over timing, target tissue and immune consequences.
Further reading